nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—HTR7—vagus nerve—esophageal cancer	0.0552	0.257	CbGeAlD
Lurasidone—HTR2A—vagus nerve—esophageal cancer	0.0344	0.16	CbGeAlD
Lurasidone—Joint stiffness—Capecitabine—esophageal cancer	0.0169	0.03	CcSEcCtD
Lurasidone—Trismus—Capecitabine—esophageal cancer	0.0153	0.0271	CcSEcCtD
Lurasidone—Panic attack—Capecitabine—esophageal cancer	0.0137	0.0243	CcSEcCtD
Lurasidone—HTR7—neck—esophageal cancer	0.0121	0.0564	CbGeAlD
Lurasidone—Serum creatinine increased—Cisplatin—esophageal cancer	0.0112	0.02	CcSEcCtD
Lurasidone—Sudden death—Capecitabine—esophageal cancer	0.00996	0.0177	CcSEcCtD
Lurasidone—Deep vein thrombosis—Capecitabine—esophageal cancer	0.00838	0.0149	CcSEcCtD
Lurasidone—Infection—Carboplatin—esophageal cancer	0.00835	0.0148	CcSEcCtD
Lurasidone—Serum creatinine increased—Capecitabine—esophageal cancer	0.00828	0.0147	CcSEcCtD
Lurasidone—HTR7—epithelium—esophageal cancer	0.00824	0.0384	CbGeAlD
Lurasidone—HTR7—smooth muscle tissue—esophageal cancer	0.00794	0.037	CbGeAlD
Lurasidone—HTR2A—neck—esophageal cancer	0.00755	0.0352	CbGeAlD
Lurasidone—ADRA2C—bronchus—esophageal cancer	0.00746	0.0347	CbGeAlD
Lurasidone—Sudden death—Methotrexate—esophageal cancer	0.00741	0.0132	CcSEcCtD
Lurasidone—Dysarthria—Cisplatin—esophageal cancer	0.00731	0.013	CcSEcCtD
Lurasidone—HTR7—trachea—esophageal cancer	0.00728	0.0339	CbGeAlD
Lurasidone—Torsade de pointes—Capecitabine—esophageal cancer	0.00727	0.0129	CcSEcCtD
Lurasidone—ADRA2C—trachea—esophageal cancer	0.00669	0.0312	CbGeAlD
Lurasidone—HTR7—digestive system—esophageal cancer	0.00627	0.0292	CbGeAlD
Lurasidone—Deep vein thrombosis—Methotrexate—esophageal cancer	0.00623	0.0111	CcSEcCtD
Lurasidone—ADRA2A—bronchus—esophageal cancer	0.00595	0.0277	CbGeAlD
Lurasidone—Musculoskeletal stiffness—Capecitabine—esophageal cancer	0.00568	0.0101	CcSEcCtD
Lurasidone—Dysarthria—Capecitabine—esophageal cancer	0.00539	0.00957	CcSEcCtD
Lurasidone—ADRA2A—trachea—esophageal cancer	0.00534	0.0249	CbGeAlD
Lurasidone—HTR7—lung—esophageal cancer	0.00523	0.0244	CbGeAlD
Lurasidone—Gait disturbance—Capecitabine—esophageal cancer	0.00522	0.00927	CcSEcCtD
Lurasidone—Neck pain—Capecitabine—esophageal cancer	0.00516	0.00916	CcSEcCtD
Lurasidone—HTR2A—epithelium—esophageal cancer	0.00514	0.0239	CbGeAlD
Lurasidone—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00512	0.00909	CcSEcCtD
Lurasidone—Pulmonary embolism—Capecitabine—esophageal cancer	0.0051	0.00905	CcSEcCtD
Lurasidone—Blood pressure increased—Capecitabine—esophageal cancer	0.0051	0.00905	CcSEcCtD
Lurasidone—HTR2A—smooth muscle tissue—esophageal cancer	0.00495	0.0231	CbGeAlD
Lurasidone—DRD2—lung—esophageal cancer	0.00495	0.0231	CbGeAlD
Lurasidone—ADRA2C—lung—esophageal cancer	0.00481	0.0224	CbGeAlD
Lurasidone—Blood creatinine increased—Cisplatin—esophageal cancer	0.0047	0.00835	CcSEcCtD
Lurasidone—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00458	0.00814	CcSEcCtD
Lurasidone—HTR2A—trachea—esophageal cancer	0.00454	0.0212	CbGeAlD
Lurasidone—Breast disorder—Cisplatin—esophageal cancer	0.00453	0.00805	CcSEcCtD
Lurasidone—Nasopharyngitis—Cisplatin—esophageal cancer	0.00449	0.00797	CcSEcCtD
Lurasidone—Sleep disorder—Capecitabine—esophageal cancer	0.00427	0.00759	CcSEcCtD
Lurasidone—Diabetes mellitus—Capecitabine—esophageal cancer	0.00425	0.00755	CcSEcCtD
Lurasidone—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.00423	0.00751	CcSEcCtD
Lurasidone—Abdominal discomfort—Cisplatin—esophageal cancer	0.00416	0.00738	CcSEcCtD
Lurasidone—Dysarthria—Methotrexate—esophageal cancer	0.00401	0.00712	CcSEcCtD
Lurasidone—Hot flush—Capecitabine—esophageal cancer	0.00395	0.00702	CcSEcCtD
Lurasidone—Increased appetite—Capecitabine—esophageal cancer	0.00394	0.00699	CcSEcCtD
Lurasidone—Menopausal symptoms—Capecitabine—esophageal cancer	0.00392	0.00696	CcSEcCtD
Lurasidone—HTR2A—digestive system—esophageal cancer	0.00391	0.0182	CbGeAlD
Lurasidone—ADRA2A—lung—esophageal cancer	0.00384	0.0179	CbGeAlD
Lurasidone—Renal failure—Cisplatin—esophageal cancer	0.0038	0.00675	CcSEcCtD
Lurasidone—Pulmonary embolism—Methotrexate—esophageal cancer	0.00379	0.00674	CcSEcCtD
Lurasidone—Lethargy—Capecitabine—esophageal cancer	0.00377	0.0067	CcSEcCtD
Lurasidone—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00377	0.0067	CcSEcCtD
Lurasidone—Osteoarthritis—Capecitabine—esophageal cancer	0.0037	0.00657	CcSEcCtD
Lurasidone—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00366	0.00649	CcSEcCtD
Lurasidone—CYP3A4—digestive system—esophageal cancer	0.00362	0.0169	CbGeAlD
Lurasidone—Bradycardia—Cisplatin—esophageal cancer	0.00353	0.00628	CcSEcCtD
Lurasidone—Blood creatinine increased—Capecitabine—esophageal cancer	0.00346	0.00615	CcSEcCtD
Lurasidone—Urinary tract disorder—Cisplatin—esophageal cancer	0.00343	0.00609	CcSEcCtD
Lurasidone—Connective tissue disorder—Cisplatin—esophageal cancer	0.00341	0.00606	CcSEcCtD
Lurasidone—Urethral disorder—Cisplatin—esophageal cancer	0.0034	0.00604	CcSEcCtD
Lurasidone—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00338	0.006	CcSEcCtD
Lurasidone—Abdominal pain upper—Capecitabine—esophageal cancer	0.00338	0.006	CcSEcCtD
Lurasidone—Breast disorder—Capecitabine—esophageal cancer	0.00334	0.00594	CcSEcCtD
Lurasidone—Nasopharyngitis—Capecitabine—esophageal cancer	0.00331	0.00587	CcSEcCtD
Lurasidone—ADRA2C—lymph node—esophageal cancer	0.00329	0.0153	CbGeAlD
Lurasidone—Gastritis—Capecitabine—esophageal cancer	0.00327	0.00581	CcSEcCtD
Lurasidone—HTR2A—lung—esophageal cancer	0.00326	0.0152	CbGeAlD
Lurasidone—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00326	0.00579	CcSEcCtD
Lurasidone—Eye disorder—Cisplatin—esophageal cancer	0.00324	0.00576	CcSEcCtD
Lurasidone—Cardiac disorder—Cisplatin—esophageal cancer	0.00322	0.00572	CcSEcCtD
Lurasidone—Influenza—Capecitabine—esophageal cancer	0.0032	0.00568	CcSEcCtD
Lurasidone—Dysphagia—Capecitabine—esophageal cancer	0.0032	0.00568	CcSEcCtD
Lurasidone—Diabetes mellitus—Methotrexate—esophageal cancer	0.00317	0.00562	CcSEcCtD
Lurasidone—Angina pectoris—Capecitabine—esophageal cancer	0.00311	0.00553	CcSEcCtD
Lurasidone—Arrhythmia—Cisplatin—esophageal cancer	0.0031	0.00551	CcSEcCtD
Lurasidone—Abdominal discomfort—Capecitabine—esophageal cancer	0.00306	0.00544	CcSEcCtD
Lurasidone—Malnutrition—Cisplatin—esophageal cancer	0.00302	0.00537	CcSEcCtD
Lurasidone—Dysuria—Capecitabine—esophageal cancer	0.00299	0.00531	CcSEcCtD
Lurasidone—Neutropenia—Capecitabine—esophageal cancer	0.00299	0.00531	CcSEcCtD
Lurasidone—Flatulence—Cisplatin—esophageal cancer	0.00298	0.00529	CcSEcCtD
Lurasidone—Weight increased—Capecitabine—esophageal cancer	0.00291	0.00517	CcSEcCtD
Lurasidone—Muscle spasms—Cisplatin—esophageal cancer	0.0029	0.00516	CcSEcCtD
Lurasidone—Hyperglycaemia—Capecitabine—esophageal cancer	0.00288	0.00512	CcSEcCtD
Lurasidone—Infestation—Capecitabine—esophageal cancer	0.00285	0.00506	CcSEcCtD
Lurasidone—Infestation NOS—Capecitabine—esophageal cancer	0.00285	0.00506	CcSEcCtD
Lurasidone—Vision blurred—Cisplatin—esophageal cancer	0.00285	0.00506	CcSEcCtD
Lurasidone—Tremor—Cisplatin—esophageal cancer	0.00283	0.00503	CcSEcCtD
Lurasidone—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00281	0.00499	CcSEcCtD
Lurasidone—Lethargy—Methotrexate—esophageal cancer	0.00281	0.00499	CcSEcCtD
Lurasidone—Renal failure—Capecitabine—esophageal cancer	0.0028	0.00498	CcSEcCtD
Lurasidone—Anaemia—Cisplatin—esophageal cancer	0.00279	0.00496	CcSEcCtD
Lurasidone—Urinary tract infection—Capecitabine—esophageal cancer	0.00277	0.00492	CcSEcCtD
Lurasidone—Osteoarthritis—Methotrexate—esophageal cancer	0.00275	0.00489	CcSEcCtD
Lurasidone—Malaise—Cisplatin—esophageal cancer	0.00272	0.00484	CcSEcCtD
Lurasidone—Leukopenia—Cisplatin—esophageal cancer	0.0027	0.0048	CcSEcCtD
Lurasidone—Hepatobiliary disease—Capecitabine—esophageal cancer	0.0027	0.00479	CcSEcCtD
Lurasidone—Agranulocytosis—Capecitabine—esophageal cancer	0.00266	0.00472	CcSEcCtD
Lurasidone—ADRA2A—lymph node—esophageal cancer	0.00262	0.0122	CbGeAlD
Lurasidone—Convulsion—Cisplatin—esophageal cancer	0.00262	0.00465	CcSEcCtD
Lurasidone—Bradycardia—Capecitabine—esophageal cancer	0.0026	0.00463	CcSEcCtD
Lurasidone—Myalgia—Cisplatin—esophageal cancer	0.00257	0.00457	CcSEcCtD
Lurasidone—Anxiety—Cisplatin—esophageal cancer	0.00256	0.00455	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00255	0.00454	CcSEcCtD
Lurasidone—Urinary tract disorder—Capecitabine—esophageal cancer	0.00253	0.00449	CcSEcCtD
Lurasidone—Connective tissue disorder—Capecitabine—esophageal cancer	0.00251	0.00447	CcSEcCtD
Lurasidone—Urethral disorder—Capecitabine—esophageal cancer	0.00251	0.00445	CcSEcCtD
Lurasidone—Breast disorder—Methotrexate—esophageal cancer	0.00249	0.00442	CcSEcCtD
Lurasidone—Infection—Cisplatin—esophageal cancer	0.00245	0.00435	CcSEcCtD
Lurasidone—Nervous system disorder—Cisplatin—esophageal cancer	0.00242	0.00429	CcSEcCtD
Lurasidone—Tachycardia—Cisplatin—esophageal cancer	0.00241	0.00427	CcSEcCtD
Lurasidone—Skin disorder—Cisplatin—esophageal cancer	0.0024	0.00425	CcSEcCtD
Lurasidone—Eye disorder—Capecitabine—esophageal cancer	0.00239	0.00425	CcSEcCtD
Lurasidone—Hyperhidrosis—Cisplatin—esophageal cancer	0.00238	0.00423	CcSEcCtD
Lurasidone—Cardiac disorder—Capecitabine—esophageal cancer	0.00237	0.00422	CcSEcCtD
Lurasidone—Eosinophilia—Methotrexate—esophageal cancer	0.00236	0.00418	CcSEcCtD
Lurasidone—Angiopathy—Capecitabine—esophageal cancer	0.00232	0.00412	CcSEcCtD
Lurasidone—Hypotension—Cisplatin—esophageal cancer	0.0023	0.00409	CcSEcCtD
Lurasidone—Arrhythmia—Capecitabine—esophageal cancer	0.00229	0.00406	CcSEcCtD
Lurasidone—Abdominal discomfort—Methotrexate—esophageal cancer	0.00228	0.00405	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00225	0.00399	CcSEcCtD
Lurasidone—Mental disorder—Capecitabine—esophageal cancer	0.00224	0.00398	CcSEcCtD
Lurasidone—Malnutrition—Capecitabine—esophageal cancer	0.00223	0.00396	CcSEcCtD
Lurasidone—Dysuria—Methotrexate—esophageal cancer	0.00223	0.00395	CcSEcCtD
Lurasidone—Neutropenia—Methotrexate—esophageal cancer	0.00223	0.00395	CcSEcCtD
Lurasidone—Dyspnoea—Cisplatin—esophageal cancer	0.0022	0.0039	CcSEcCtD
Lurasidone—Flatulence—Capecitabine—esophageal cancer	0.00219	0.0039	CcSEcCtD
Lurasidone—Erectile dysfunction—Methotrexate—esophageal cancer	0.00219	0.00389	CcSEcCtD
Lurasidone—Back pain—Capecitabine—esophageal cancer	0.00215	0.00383	CcSEcCtD
Lurasidone—Decreased appetite—Cisplatin—esophageal cancer	0.00214	0.00381	CcSEcCtD
Lurasidone—Muscle spasms—Capecitabine—esophageal cancer	0.00214	0.0038	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00213	0.00378	CcSEcCtD
Lurasidone—Infestation—Methotrexate—esophageal cancer	0.00212	0.00377	CcSEcCtD
Lurasidone—Infestation NOS—Methotrexate—esophageal cancer	0.00212	0.00377	CcSEcCtD
Lurasidone—Vision blurred—Capecitabine—esophageal cancer	0.0021	0.00373	CcSEcCtD
Lurasidone—Tremor—Capecitabine—esophageal cancer	0.00209	0.00371	CcSEcCtD
Lurasidone—Renal failure—Methotrexate—esophageal cancer	0.00209	0.0037	CcSEcCtD
Lurasidone—Anaemia—Capecitabine—esophageal cancer	0.00206	0.00366	CcSEcCtD
Lurasidone—Malaise—Capecitabine—esophageal cancer	0.00201	0.00357	CcSEcCtD
Lurasidone—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00201	0.00356	CcSEcCtD
Lurasidone—Vertigo—Capecitabine—esophageal cancer	0.002	0.00355	CcSEcCtD
Lurasidone—Syncope—Capecitabine—esophageal cancer	0.002	0.00355	CcSEcCtD
Lurasidone—Leukopenia—Capecitabine—esophageal cancer	0.00199	0.00354	CcSEcCtD
Lurasidone—Agranulocytosis—Methotrexate—esophageal cancer	0.00198	0.00352	CcSEcCtD
Lurasidone—Loss of consciousness—Capecitabine—esophageal cancer	0.00196	0.00348	CcSEcCtD
Lurasidone—Hypertension—Capecitabine—esophageal cancer	0.00192	0.00342	CcSEcCtD
Lurasidone—Myalgia—Capecitabine—esophageal cancer	0.0019	0.00337	CcSEcCtD
Lurasidone—Anxiety—Capecitabine—esophageal cancer	0.00189	0.00336	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00188	0.00334	CcSEcCtD
Lurasidone—Urinary tract disorder—Methotrexate—esophageal cancer	0.00188	0.00334	CcSEcCtD
Lurasidone—Urethral disorder—Methotrexate—esophageal cancer	0.00187	0.00332	CcSEcCtD
Lurasidone—Dry mouth—Capecitabine—esophageal cancer	0.00185	0.00329	CcSEcCtD
Lurasidone—Infection—Capecitabine—esophageal cancer	0.00181	0.00321	CcSEcCtD
Lurasidone—Shock—Capecitabine—esophageal cancer	0.00179	0.00318	CcSEcCtD
Lurasidone—Nervous system disorder—Capecitabine—esophageal cancer	0.00178	0.00317	CcSEcCtD
Lurasidone—Eye disorder—Methotrexate—esophageal cancer	0.00178	0.00316	CcSEcCtD
Lurasidone—Tachycardia—Capecitabine—esophageal cancer	0.00177	0.00315	CcSEcCtD
Lurasidone—Asthenia—Cisplatin—esophageal cancer	0.00177	0.00314	CcSEcCtD
Lurasidone—Cardiac disorder—Methotrexate—esophageal cancer	0.00177	0.00314	CcSEcCtD
Lurasidone—Skin disorder—Capecitabine—esophageal cancer	0.00177	0.00314	CcSEcCtD
Lurasidone—Hyperhidrosis—Capecitabine—esophageal cancer	0.00176	0.00312	CcSEcCtD
Lurasidone—Angiopathy—Methotrexate—esophageal cancer	0.00173	0.00307	CcSEcCtD
Lurasidone—Hypotension—Capecitabine—esophageal cancer	0.0017	0.00302	CcSEcCtD
Lurasidone—Diarrhoea—Cisplatin—esophageal cancer	0.00169	0.003	CcSEcCtD
Lurasidone—Mental disorder—Methotrexate—esophageal cancer	0.00167	0.00296	CcSEcCtD
Lurasidone—Malnutrition—Methotrexate—esophageal cancer	0.00166	0.00294	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00166	0.00294	CcSEcCtD
Lurasidone—Insomnia—Capecitabine—esophageal cancer	0.00164	0.00292	CcSEcCtD
Lurasidone—Dyspnoea—Capecitabine—esophageal cancer	0.00162	0.00288	CcSEcCtD
Lurasidone—Back pain—Methotrexate—esophageal cancer	0.0016	0.00285	CcSEcCtD
Lurasidone—Dyspepsia—Capecitabine—esophageal cancer	0.0016	0.00284	CcSEcCtD
Lurasidone—Decreased appetite—Capecitabine—esophageal cancer	0.00158	0.00281	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00157	0.00279	CcSEcCtD
Lurasidone—Vomiting—Cisplatin—esophageal cancer	0.00157	0.00278	CcSEcCtD
Lurasidone—Fatigue—Capecitabine—esophageal cancer	0.00157	0.00278	CcSEcCtD
Lurasidone—Vision blurred—Methotrexate—esophageal cancer	0.00156	0.00278	CcSEcCtD
Lurasidone—Rash—Cisplatin—esophageal cancer	0.00155	0.00276	CcSEcCtD
Lurasidone—Dermatitis—Cisplatin—esophageal cancer	0.00155	0.00276	CcSEcCtD
Lurasidone—Anaemia—Methotrexate—esophageal cancer	0.00153	0.00272	CcSEcCtD
Lurasidone—Malaise—Methotrexate—esophageal cancer	0.0015	0.00266	CcSEcCtD
Lurasidone—Vertigo—Methotrexate—esophageal cancer	0.00149	0.00265	CcSEcCtD
Lurasidone—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00149	0.00264	CcSEcCtD
Lurasidone—Leukopenia—Methotrexate—esophageal cancer	0.00148	0.00264	CcSEcCtD
Lurasidone—Nausea—Cisplatin—esophageal cancer	0.00146	0.0026	CcSEcCtD
Lurasidone—Abdominal pain—Capecitabine—esophageal cancer	0.00144	0.00255	CcSEcCtD
Lurasidone—Convulsion—Methotrexate—esophageal cancer	0.00144	0.00255	CcSEcCtD
Lurasidone—Myalgia—Methotrexate—esophageal cancer	0.00141	0.00251	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.0014	0.00249	CcSEcCtD
Lurasidone—Infection—Methotrexate—esophageal cancer	0.00134	0.00239	CcSEcCtD
Lurasidone—Nervous system disorder—Methotrexate—esophageal cancer	0.00133	0.00236	CcSEcCtD
Lurasidone—Skin disorder—Methotrexate—esophageal cancer	0.00131	0.00233	CcSEcCtD
Lurasidone—Hyperhidrosis—Methotrexate—esophageal cancer	0.00131	0.00232	CcSEcCtD
Lurasidone—Asthenia—Capecitabine—esophageal cancer	0.0013	0.00232	CcSEcCtD
Lurasidone—Pruritus—Capecitabine—esophageal cancer	0.00129	0.00228	CcSEcCtD
Lurasidone—Hypotension—Methotrexate—esophageal cancer	0.00126	0.00225	CcSEcCtD
Lurasidone—Diarrhoea—Capecitabine—esophageal cancer	0.00124	0.00221	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00123	0.00219	CcSEcCtD
Lurasidone—Insomnia—Methotrexate—esophageal cancer	0.00122	0.00217	CcSEcCtD
Lurasidone—Dyspnoea—Methotrexate—esophageal cancer	0.00121	0.00214	CcSEcCtD
Lurasidone—Somnolence—Methotrexate—esophageal cancer	0.0012	0.00214	CcSEcCtD
Lurasidone—Dizziness—Capecitabine—esophageal cancer	0.0012	0.00213	CcSEcCtD
Lurasidone—Dyspepsia—Methotrexate—esophageal cancer	0.00119	0.00212	CcSEcCtD
Lurasidone—Decreased appetite—Methotrexate—esophageal cancer	0.00118	0.00209	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00117	0.00207	CcSEcCtD
Lurasidone—Fatigue—Methotrexate—esophageal cancer	0.00117	0.00207	CcSEcCtD
Lurasidone—Vomiting—Capecitabine—esophageal cancer	0.00116	0.00205	CcSEcCtD
Lurasidone—Rash—Capecitabine—esophageal cancer	0.00115	0.00204	CcSEcCtD
Lurasidone—Dermatitis—Capecitabine—esophageal cancer	0.00115	0.00203	CcSEcCtD
Lurasidone—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00111	0.00197	CcSEcCtD
Lurasidone—Nausea—Capecitabine—esophageal cancer	0.00108	0.00192	CcSEcCtD
Lurasidone—Abdominal pain—Methotrexate—esophageal cancer	0.00107	0.0019	CcSEcCtD
Lurasidone—Asthenia—Methotrexate—esophageal cancer	0.000971	0.00172	CcSEcCtD
Lurasidone—Pruritus—Methotrexate—esophageal cancer	0.000957	0.0017	CcSEcCtD
Lurasidone—Diarrhoea—Methotrexate—esophageal cancer	0.000926	0.00164	CcSEcCtD
Lurasidone—Dizziness—Methotrexate—esophageal cancer	0.000895	0.00159	CcSEcCtD
Lurasidone—Vomiting—Methotrexate—esophageal cancer	0.00086	0.00153	CcSEcCtD
Lurasidone—Rash—Methotrexate—esophageal cancer	0.000853	0.00152	CcSEcCtD
Lurasidone—Dermatitis—Methotrexate—esophageal cancer	0.000852	0.00151	CcSEcCtD
Lurasidone—Nausea—Methotrexate—esophageal cancer	0.000804	0.00143	CcSEcCtD
Lurasidone—HTR2A—Signaling Pathways—AKAP13—esophageal cancer	0.000135	0.000608	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—CRABP1—esophageal cancer	0.000135	0.000605	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—GNG7—esophageal cancer	0.000132	0.000593	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—ENO1—esophageal cancer	0.000132	0.000592	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PTGS1—esophageal cancer	0.000132	0.000592	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PSME2—esophageal cancer	0.00013	0.000583	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PSME1—esophageal cancer	0.00013	0.000583	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—GNG7—esophageal cancer	0.000128	0.000576	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—NOTCH2—esophageal cancer	0.000128	0.000576	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—XIAP—esophageal cancer	0.000128	0.000574	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000127	0.00057	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ELMO1—esophageal cancer	0.000126	0.000566	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PDE4D—esophageal cancer	0.000126	0.000565	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000125	0.000561	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PDE4D—esophageal cancer	0.000124	0.000556	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—XIAP—esophageal cancer	0.000123	0.000555	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—CREBBP—esophageal cancer	0.000123	0.000555	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—AKAP13—esophageal cancer	0.000123	0.000553	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CTNNA1—esophageal cancer	0.000121	0.000543	CbGpPWpGaD
Lurasidone—ADRA2A—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	0.000121	0.000542	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CXCL2—esophageal cancer	0.00012	0.00054	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—ALDH2—esophageal cancer	0.00012	0.000539	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—GNG7—esophageal cancer	0.00012	0.000538	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—GNG7—esophageal cancer	0.000118	0.000529	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CTNNA1—esophageal cancer	0.000117	0.000525	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CXCL2—esophageal cancer	0.000116	0.000522	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000114	0.000515	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000114	0.000515	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—GSTT1—esophageal cancer	0.000114	0.000513	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000114	0.000511	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TGFBR2—esophageal cancer	0.000114	0.000511	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—CYP2A6—esophageal cancer	0.000113	0.000507	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PDE4D—esophageal cancer	0.000113	0.000506	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PSME2—esophageal cancer	0.000112	0.000504	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PSME1—esophageal cancer	0.000112	0.000504	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—XIAP—esophageal cancer	0.000112	0.000504	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—CYP1B1—esophageal cancer	0.000112	0.000503	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—ANXA1—esophageal cancer	0.000112	0.000502	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—NOS3—esophageal cancer	0.00011	0.000497	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—XIAP—esophageal cancer	0.00011	0.000496	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—SST—esophageal cancer	0.000109	0.000488	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PSME2—esophageal cancer	0.000108	0.000488	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PSME1—esophageal cancer	0.000108	0.000488	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—ANXA1—esophageal cancer	0.000108	0.000485	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—SMAD4—esophageal cancer	0.000107	0.000483	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—GNG7—esophageal cancer	0.000107	0.000481	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—ENO1—esophageal cancer	0.000107	0.000481	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PTGS1—esophageal cancer	0.000107	0.000481	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CTNNA1—esophageal cancer	0.000106	0.000477	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—GHRL—esophageal cancer	0.000106	0.000476	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NOTCH3—esophageal cancer	0.000106	0.000476	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PSME1—esophageal cancer	0.000105	0.000474	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PSME2—esophageal cancer	0.000105	0.000474	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CXCL2—esophageal cancer	0.000105	0.000474	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—CYP19A1—esophageal cancer	0.000105	0.000473	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—SST—esophageal cancer	0.000105	0.000472	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CTNNA1—esophageal cancer	0.000104	0.000469	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—FBXW7—esophageal cancer	0.000104	0.000468	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CXCL2—esophageal cancer	0.000104	0.000466	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—EP300—esophageal cancer	0.000103	0.000465	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NOTCH3—esophageal cancer	0.000102	0.00046	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—GHRL—esophageal cancer	0.000102	0.00046	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—FBXW7—esophageal cancer	0.000101	0.000453	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—XIAP—esophageal cancer	0.0001	0.000451	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PSME2—esophageal cancer	9.84e-05	0.000443	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PSME1—esophageal cancer	9.84e-05	0.000443	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—ANXA1—esophageal cancer	9.79e-05	0.00044	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—SLC10A2—esophageal cancer	9.73e-05	0.000438	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CA1—esophageal cancer	9.73e-05	0.000438	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PSME2—esophageal cancer	9.68e-05	0.000435	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PSME1—esophageal cancer	9.68e-05	0.000435	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—ANXA1—esophageal cancer	9.64e-05	0.000433	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—HMOX1—esophageal cancer	9.6e-05	0.000432	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—SST—esophageal cancer	9.53e-05	0.000428	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CTNNA1—esophageal cancer	9.49e-05	0.000427	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NOTCH2—esophageal cancer	9.48e-05	0.000427	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CXCL2—esophageal cancer	9.43e-05	0.000424	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—SST—esophageal cancer	9.37e-05	0.000422	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NOTCH3—esophageal cancer	9.28e-05	0.000418	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—GHRL—esophageal cancer	9.28e-05	0.000418	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—ABCB1—esophageal cancer	9.22e-05	0.000415	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NOTCH2—esophageal cancer	9.18e-05	0.000413	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NOTCH3—esophageal cancer	9.14e-05	0.000411	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—GHRL—esophageal cancer	9.14e-05	0.000411	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—FBXW7—esophageal cancer	9.13e-05	0.000411	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—CYP1B1—esophageal cancer	9.09e-05	0.000409	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—FBXW7—esophageal cancer	8.99e-05	0.000404	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CA2—esophageal cancer	8.9e-05	0.0004	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PSME1—esophageal cancer	8.81e-05	0.000396	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PSME2—esophageal cancer	8.81e-05	0.000396	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—HIF1A—esophageal cancer	8.79e-05	0.000395	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ANXA1—esophageal cancer	8.77e-05	0.000394	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—CYP19A1—esophageal cancer	8.55e-05	0.000384	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SST—esophageal cancer	8.53e-05	0.000384	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TGFBR2—esophageal cancer	8.41e-05	0.000378	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—KDR—esophageal cancer	8.41e-05	0.000378	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—EP300—esophageal cancer	8.4e-05	0.000378	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NOTCH2—esophageal cancer	8.33e-05	0.000375	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NOTCH3—esophageal cancer	8.31e-05	0.000374	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—GHRL—esophageal cancer	8.31e-05	0.000374	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ADH7—esophageal cancer	8.27e-05	0.000372	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PLCE1—esophageal cancer	8.27e-05	0.000372	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NOTCH2—esophageal cancer	8.19e-05	0.000369	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—FBXW7—esophageal cancer	8.18e-05	0.000368	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TGFBR2—esophageal cancer	8.14e-05	0.000366	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—SMAD4—esophageal cancer	7.96e-05	0.000358	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—NOTCH1—esophageal cancer	7.92e-05	0.000356	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—HMOX1—esophageal cancer	7.8e-05	0.000351	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—SMAD4—esophageal cancer	7.71e-05	0.000347	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—PIK3CA—esophageal cancer	7.65e-05	0.000344	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—ABCB1—esophageal cancer	7.49e-05	0.000337	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NOTCH2—esophageal cancer	7.45e-05	0.000335	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—TP53—esophageal cancer	7.4e-05	0.000333	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TGFBR2—esophageal cancer	7.39e-05	0.000332	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TGFBR2—esophageal cancer	7.27e-05	0.000327	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ADH1B—esophageal cancer	7.25e-05	0.000326	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CREBBP—esophageal cancer	7.18e-05	0.000323	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—EGFR—esophageal cancer	7.06e-05	0.000317	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—SMAD4—esophageal cancer	6.99e-05	0.000314	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—TYMP—esophageal cancer	6.93e-05	0.000312	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—SMAD4—esophageal cancer	6.88e-05	0.000309	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—PIK3CA—esophageal cancer	6.75e-05	0.000303	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP26A1—esophageal cancer	6.74e-05	0.000303	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TGFBR2—esophageal cancer	6.61e-05	0.000297	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ALOX15—esophageal cancer	6.57e-05	0.000296	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—HIF1A—esophageal cancer	6.52e-05	0.000293	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—NOS3—esophageal cancer	6.43e-05	0.000289	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—HIF1A—esophageal cancer	6.31e-05	0.000284	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTO1—esophageal cancer	6.27e-05	0.000282	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—TPI1—esophageal cancer	6.27e-05	0.000282	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SMAD4—esophageal cancer	6.26e-05	0.000282	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—KDR—esophageal cancer	6.23e-05	0.00028	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—PIK3CA—esophageal cancer	6.22e-05	0.00028	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—CREBBP—esophageal cancer	6.16e-05	0.000277	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—PIK3CA—esophageal cancer	6.13e-05	0.000276	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—KDR—esophageal cancer	6.03e-05	0.000271	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—ERBB2—esophageal cancer	6.02e-05	0.000271	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—TP53—esophageal cancer	6.01e-05	0.00027	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ALDOB—esophageal cancer	6.01e-05	0.00027	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NOTCH1—esophageal cancer	5.87e-05	0.000264	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GAPDH—esophageal cancer	5.79e-05	0.00026	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CRABP1—esophageal cancer	5.73e-05	0.000258	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—HIF1A—esophageal cancer	5.72e-05	0.000257	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NOTCH1—esophageal cancer	5.68e-05	0.000255	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—HIF1A—esophageal cancer	5.63e-05	0.000253	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—NOS3—esophageal cancer	5.52e-05	0.000248	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—KDR—esophageal cancer	5.47e-05	0.000246	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GNG7—esophageal cancer	5.45e-05	0.000245	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—KDR—esophageal cancer	5.38e-05	0.000242	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CREBBP—esophageal cancer	5.32e-05	0.000239	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CCND1—esophageal cancer	5.31e-05	0.000239	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	5.23e-05	0.000235	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NOTCH1—esophageal cancer	5.15e-05	0.000232	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CREBBP—esophageal cancer	5.15e-05	0.000232	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CDKN1A—esophageal cancer	5.14e-05	0.000231	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—HIF1A—esophageal cancer	5.12e-05	0.00023	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ALDH2—esophageal cancer	5.11e-05	0.00023	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	5.07e-05	0.000228	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—EGFR—esophageal cancer	5.06e-05	0.000228	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PTGS2—esophageal cancer	5.04e-05	0.000227	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—CREBBP—esophageal cancer	5e-05	0.000225	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	5e-05	0.000225	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—KDR—esophageal cancer	4.9e-05	0.00022	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—EP300—esophageal cancer	4.89e-05	0.00022	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTT1—esophageal cancer	4.86e-05	0.000219	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—PIK3CA—esophageal cancer	4.84e-05	0.000218	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP2A6—esophageal cancer	4.8e-05	0.000216	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NOS3—esophageal cancer	4.77e-05	0.000214	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CREBBP—esophageal cancer	4.67e-05	0.00021	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	4.61e-05	0.000208	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NOS3—esophageal cancer	4.61e-05	0.000207	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	4.6e-05	0.000207	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—EGFR—esophageal cancer	4.59e-05	0.000207	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ENO1—esophageal cancer	4.56e-05	0.000205	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PTGS1—esophageal cancer	4.56e-05	0.000205	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	4.54e-05	0.000204	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	4.52e-05	0.000203	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PSME1—esophageal cancer	4.49e-05	0.000202	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PSME2—esophageal cancer	4.49e-05	0.000202	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—NOS3—esophageal cancer	4.48e-05	0.000201	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	4.46e-05	0.0002	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—PIK3CA—esophageal cancer	4.39e-05	0.000198	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	4.39e-05	0.000197	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	4.32e-05	0.000194	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—ERBB2—esophageal cancer	4.31e-05	0.000194	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MYC—esophageal cancer	4.26e-05	0.000192	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—EP300—esophageal cancer	4.2e-05	0.000189	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NOS3—esophageal cancer	4.18e-05	0.000188	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	4.18e-05	0.000188	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—EGFR—esophageal cancer	4.17e-05	0.000188	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NOS3—esophageal cancer	4.12e-05	0.000185	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	4.11e-05	0.000185	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PTGS2—esophageal cancer	4.1e-05	0.000184	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	3.99e-05	0.000179	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCND1—esophageal cancer	3.94e-05	0.000177	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	3.93e-05	0.000177	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	3.92e-05	0.000176	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—ERBB2—esophageal cancer	3.91e-05	0.000176	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP1B1—esophageal cancer	3.87e-05	0.000174	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	3.85e-05	0.000173	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCND1—esophageal cancer	3.81e-05	0.000171	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	3.81e-05	0.000171	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	3.75e-05	0.000168	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CDKN1A—esophageal cancer	3.69e-05	0.000166	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP19A1—esophageal cancer	3.64e-05	0.000164	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—EP300—esophageal cancer	3.63e-05	0.000163	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—PIK3CA—esophageal cancer	3.62e-05	0.000163	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	3.57e-05	0.00016	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—EP300—esophageal cancer	3.51e-05	0.000158	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	3.5e-05	0.000158	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TP53—esophageal cancer	3.5e-05	0.000157	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCND1—esophageal cancer	3.46e-05	0.000156	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—EP300—esophageal cancer	3.41e-05	0.000153	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCND1—esophageal cancer	3.4e-05	0.000153	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	3.35e-05	0.00015	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—HMOX1—esophageal cancer	3.32e-05	0.000149	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	3.29e-05	0.000148	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ABCB1—esophageal cancer	3.19e-05	0.000143	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—EP300—esophageal cancer	3.18e-05	0.000143	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MYC—esophageal cancer	3.16e-05	0.000142	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—EP300—esophageal cancer	3.13e-05	0.000141	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PIK3CA—esophageal cancer	3.1e-05	0.00014	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	3.1e-05	0.000139	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—EGFR—esophageal cancer	3.09e-05	0.000139	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MYC—esophageal cancer	3.06e-05	0.000137	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	2.99e-05	0.000135	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—EGFR—esophageal cancer	2.99e-05	0.000134	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EP300—esophageal cancer	2.85e-05	0.000128	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MYC—esophageal cancer	2.77e-05	0.000125	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MYC—esophageal cancer	2.73e-05	0.000123	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—EGFR—esophageal cancer	2.71e-05	0.000122	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	2.68e-05	0.000121	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—EGFR—esophageal cancer	2.67e-05	0.00012	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CA—esophageal cancer	2.6e-05	0.000117	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TP53—esophageal cancer	2.59e-05	0.000117	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CA—esophageal cancer	2.52e-05	0.000113	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TP53—esophageal cancer	2.51e-05	0.000113	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MYC—esophageal cancer	2.48e-05	0.000112	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	2.43e-05	0.000109	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	2.35e-05	0.000106	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	2.32e-05	0.000104	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TP53—esophageal cancer	2.28e-05	0.000102	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TP53—esophageal cancer	2.24e-05	0.000101	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.13e-05	9.59e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	2.11e-05	9.48e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TP53—esophageal cancer	2.04e-05	9.17e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NOS3—esophageal cancer	1.91e-05	8.58e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.75e-05	7.85e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—EP300—esophageal cancer	1.45e-05	6.53e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.07e-05	4.83e-05	CbGpPWpGaD
